Diagnostic impact and reproducibility of p53 immunohistochemistry in Barrett's oesophagus: results of the Dutch Esophageal Pathology Panel ( DEPP )
Histopathology · 2026-10 · 89 (4) · 614-623
DOI: 10.1111/his.70193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, online erschienen am 19.06.2026. Verfasst von Ylva A Weeda und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Amsterdam University Medical Center at the University of Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Barrett Esophagus, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Kankerbestrijding, Maag Lever Darm Stichting.
Abstract (Originalsprache)
Introduction
Evidence supporting the use of p53 immunohistochemistry (p53‐IHC) in Barrett's oesophagus (BE) is largely based on selected series, limiting generalizability. This study evaluates p53‐IHC in a nationwide, real‐world BE‐cohort within a universal healthcare system, assessing concordance with referring hospitals, interobserver agreement (IOA) and its impact on routine diagnostic decisions.
Methods
Revision cases submitted to the Dutch Esophageal Pathology Panel (DEPP) were assessed by trained and experienced pathologists for haematoxylin and eosin (H&E)‐based classification (Vienna classification), p53‐IHC patterns (wild‐type, overexpression, double clone, null mutation and equivocal) and combined H&E/p53‐IHC review. Concordance between referring hospitals and the expert panel (Cohen's kappa) and IOA among panel pathologists (Fleiss' kappa) were assessed, along with the impact of p53‐IHC on diagnostic reclassification.
Results
A total of 1,146 consecutive patient consultation cases (1,704 biopsy levels) were included, with a median of 12 DEPP pathologist assessments per biopsy. Overall concordance of p53 assessment between referring hospitals and the expert panel was moderate‐to‐substantial ( κ = 0.61, 95% CI 0.58–0.64), with 24.2% of p53‐IHC assessments reclassified. IOA among 13 pathologists assessing 316 endoscopic biopsies was substantial ( κ = 0.65, 95% CI 0.61–0.69). Ancillary p53‐IHC influenced pathologists' decisions across biopsy levels. For non‐dysplastic (NDBE) biopsies, aberrant p53‐IHC prompted reclassification to indefinite for dysplasia (IND, 9.2%) or low‐grade dysplasia (LGD, 4.8%). For IND biopsies, p53‐IHC shifted diagnoses toward NDBE (17.0%) or LGD (37.1%). Conclusion/discussion p53‐IHC interpretation is reliable, reproducible and clinically meaningful in BE diagnostics when standardized criteria are applied. These findings support broader use of p53‐IHC in routine practice and incorporation of assessment criteria into guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Amsterdam University Medical Center at the University of Amsterdam, Amsterdam, the Netherlands.
- Cancer Center Amsterdam, Biomarkers, Amsterdam, the Netherlands.
- Department of Biomedical Engineering and Physics, Amsterdam University Medical Center at the University of Amsterdam, Amsterdam, the Netherlands.
- Department of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
- Department of Pathology, Erasmus University Medical Center, Rotterdam, the Netherlands.
- Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, the Netherlands.
ORCID-Profile: Ylva A Weeda, Sarah M Issa, Hans Halfwerk, Michel Botros, Onno J de Boer, Lodewijk A Brosens, Michail Doukas, Gursah Kats-Ugurlu, Fiebo Ten Kate, Lindsey Oudijk, Rachel S van der Post, Mihaela G Raicu, Bert Timmer, Myrtle J van der Wel, Sybren L Meijer
Förderung
- KWF Kankerbestrijding
- Maag Lever Darm Stichting
Zitieren
APA
Weeda, Y. A., Issa, S. M., Halfwerk, H., Botros, M., de Boer, O. J., Brosens, L. A., Doukas, M., Kats-Ugurlu, G., Ten Kate, F., van der Laan, J., van Lijnschoten, I., Ooms, A. H. A. G., Oudijk, L., van der Post, R. S., Raicu, M. G., Timmer, B., van der Wel, M. J., & Meijer, S. L. (2026). Diagnostic impact and reproducibility of p53 immunohistochemistry in Barrett's oesophagus: results of the Dutch Esophageal Pathology Panel ( DEPP ). Histopathology, 89(4), 614-623. https://doi.org/10.1111/his.70193
Vancouver
Weeda YA, Issa SM, Halfwerk H, Botros M, de Boer OJ, Brosens LA, et al. Diagnostic impact and reproducibility of p53 immunohistochemistry in Barrett's oesophagus: results of the Dutch Esophageal Pathology Panel ( DEPP ). Histopathology. 2026;89(4):614-623. doi:10.1111/his.70193
BibTeX
@article{Weeda2026,
author = {Weeda, Ylva A and Issa, Sarah M and Halfwerk, Hans and Botros, Michel and de Boer, Onno J and Brosens, Lodewijk A and Doukas, Michail and Kats-Ugurlu, Gursah and Ten Kate, Fiebo and van der Laan, Jaap and van Lijnschoten, Ineke and Ooms, Ariadne H A G and Oudijk, Lindsey and van der Post, Rachel S and Raicu, Mihaela G and Timmer, Bert and van der Wel, Myrtle J and Meijer, Sybren L},
title = {Diagnostic impact and reproducibility of p53 immunohistochemistry in Barrett's oesophagus: results of the Dutch Esophageal Pathology Panel ( DEPP )},
journal = {Histopathology},
year = {2026},
volume = {89},
number = {4},
pages = {614--623},
doi = {10.1111/his.70193}
}
EUVIMED